Skip to main content
ACG 2025 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream

Monday Poster Session

Category: Colon

P2443 - Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) on Colonoscopy: A Systematic Review and Meta-Analysis

Monday, October 27, 2025
10:30 AM - 4:00 PM MT
Location: Exhibit Hall

    Presenting Author(s)

  • GS

    Gurjot Singh, DO

    The Warren Alpert Medical School of Brown University
    Warwick, RI

Gurjot Singh, DO1, Banreet Dhindsa, MD2, Eric Berthiaume, MD3
1The Warren Alpert Medical School of Brown University, Warwick, RI; 2Brown University / Rhode Island Hospital, East Providence, RI; 3Kent Hospital, Warwick, RI

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1) are a class of medications that act by slowing gastric emptying, suppressing appetite, and stimulating insulin secretion. These medications are widely used in diabetics and management of obesity. The impact of this class of medications on the quality of colonoscopy preparation still remains unclear.

Methods: A systematic review of literature using databases such as Embase, PubMed, Google Scholar, Ovid, and Cochrane was screened for articles from October, 2024-November, 2024 using keywords of colonoscopy preparation and GLP-1 RA. Primary outcomes of interest were Boston Bowel Preparation Scale (BBPS) scores and adequacy of bowel preparation mainly defined in literature as a BBPS score of ≥6. Statistical analysis was completed with R using both a common effect model and a random effect model.

Results: A total of 11 studies which included 1,388 individuals on GLP-1 RA and 49,439 controls was analyzed. There was no significant difference in the odds ratio of individuals on a GLP-1 RA vs. individuals not on a GLP-1 RA in the overall adequacy of bowel preparation [OR 0.85, 95% CI [0.73-1.09]]. It is to be noted that although no significant difference is demonstrated in the adequacy versus inadequacy of the bowel preparation the standardized mean difference for 10 studies which reported the mean BBPS did demonstrate on average to have a lower BBPS value compared to the control arm [-0.50, 95% CI [-0.80-(-0.20)].

Discussion: GLP-1 RA do not affect the adequacy of bowel preparation however, are noted to have on average a lower BBPS score compared to those not on GLP-1 RA.


Figure: No significant difference in the odds ratio of individuals on a GLP-1 RA vs. individuals not on a GLP-1 RA in the overall adequacy of bowel preparation [OR 0.85, 95% CI [0.73-1.09]].


Figure: Mean BBPS demonstrated, on average, to have a lower BBPS value compared to the control arm [-0.50, 95% CI [-0.80-(-0.20)].

Disclosures:
Gurjot Singh indicated no relevant financial relationships.
Banreet Dhindsa indicated no relevant financial relationships.
Eric Berthiaume indicated no relevant financial relationships.

Gurjot Singh, DO1, Banreet Dhindsa, MD2, Eric Berthiaume, MD3. P2443 - Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) on Colonoscopy: A Systematic Review and Meta-Analysis, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.